{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T06:42:26Z","timestamp":1697006546558},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2007,8,15]],"date-time":"2007-08-15T00:00:00Z","timestamp":1187136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Pharma Physio"],"published-print":{"date-parts":[[2008,1]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>\n<jats:list list-type=\"explicit-label\">\n<jats:list-item><jats:p>Direct haemoperfusion through a network of fibres immobilizing polymyxin B (PMX\u2010B) is used for the treatment of septic shock, but the mechanism underlying its clinical benefits remains unclear. The aims of the present study were to assess the actions of direct haemoperfusion through fibres immobilizing PMX\u2010B (PMX\u2010DHP) on the effects of exogenously administered endotoxin in conscious guinea\u2010pigs and to examine the difference in the effects of heparin compared with nafamostat mesilate (NM) used as an anticoagulant. Although nafamostat is widely used in Japan, the agent cannot necessarily be used elsewhere in the world. Therefore, the study aimed to investigate and elucidate the effectiveness of NM compared with heparin.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Colonic motion was monitored continuously via telemetry using a force transducer attached to the taenia caecum, whereas blood pressure was monitored using a carotid artery catheter. To establish a haemoperfusion circuit in each freely moving and conscious guinea\u2010pig, catheters were implanted in the carotid artery and the jugular vein, tunnelled subcutaneously, exteriorized at the back of the neck in contact with a lightweight tethering spring and attached to a swivel device at the top of the cage. On the day after the operation, lipopolysaccharide (LPS; <jats:italic>Escherichia coli<\/jats:italic>, O111:B4; 1\u00a0mg\/kg) was administered i.v. and PMX\u2010DHP was conducted for 2\u00a0h. Heparin (50\u00a0IU\/h) or NM (0.4\u00a0mg\/h) was used as the anticoagulant. Furthermore, guinea\u2010pigs were administered a lethal dose of LPS (10\u00a0mg\/kg) and the survival rate was examined for animals undergoing PMX\u2010DHP compared with control animals.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>In guinea\u2010pigs treated with PMX\u2010DHP, relaxation of colonic longitudinal muscle caused by LPS was significantly suppressed, as were decreases in blood pressure. Of the two anticoagulants used, NM was more effective than heparin. In addition, PMX\u2010DHP significantly increased the survival rate of guinea\u2010pigs that received potentially lethal doses of LPS.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>In ca onscious and unrestrained guinea\u2010pig endotoxaemia model, PMX\u2010DHP significantly improved intestinal paralysis and decreases in blood pressure. These effects were augmented more by NM than by heparin when an anticoagulant was used in the perfusion process. These findings suggest that haemoperfusion using PMX and NM performed in the early stage of endotoxaemia is an effective treatment.<\/jats:p><\/jats:list-item>\n<\/jats:list>\n<\/jats:p>","DOI":"10.1111\/j.1440-1681.2007.04741.x","type":"journal-article","created":{"date-parts":[[2007,8,17]],"date-time":"2007-08-17T04:59:26Z","timestamp":1187326766000},"page":"17-22","source":"Crossref","is-referenced-by-count":6,"title":["EFFECTS OF DIRECT HAEMOPERFUSION THROUGH FIBRES IMMOBILIZING POLYMYXIN B AND NAFAMOSTAT MESILATE ON ENDOTOXAEMIA IN CONSCIOUS GUINEA\u2010PIGS"],"prefix":"10.1111","volume":"35","author":[{"given":"Yuichi","family":"Nakanowatari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayo","family":"Nemoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syunsuke","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norifumi","family":"Ninomiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,8,15]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0140-6736(05)60602-2","article-title":"Double\u2010blind randomised controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock. NORASEPT II study group","volume":"351","author":"Abraham E","year":"1998","journal-title":"Lancet"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510470040032"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0503-517"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(00)01313-2"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.12.11.1035"},{"key":"e_1_2_6_7_2","first-page":"218","article-title":"Regulation of the endocannabinoid system in endotoxicosis of conscious guinea pigs","volume":"16","author":"Ninomiya N","year":"2005","journal-title":"J. Jpn. Assoc. Acute Med"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2006.00427.x"},{"key":"e_1_2_6_9_2","first-page":"30","article-title":"Cardiovascular effects of removing endogenous cannabinoids using direct hemoperfusion therapy with polymyxin\u2010B immobilized fiber in septic patients","volume":"7","author":"Kase Y","year":"2003","journal-title":"Jpn J. Crit. Care Endotoxemia"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1006\/abio.2001.5015"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9610(94)90126-0"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00075198-200012000-00008"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2744(81)90023-1"},{"key":"e_1_2_6_14_2","first-page":"75","article-title":"Application to the hemodialysis of protease inhibitor FUT\u2010175","volume":"12","author":"Morikawa J","year":"1983","journal-title":"Jinkouzouki"},{"key":"e_1_2_6_15_2","first-page":"10","article-title":"Chemistry of the haemostatic mechanism and its relationship to the action of heparin","volume":"36","author":"Rosenberg RD","year":"1977","journal-title":"Fed. Proc"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00421226"},{"key":"e_1_2_6_17_2","first-page":"241","article-title":"A novel experimental method for the study of intestinal paralysis due to endotoxicosis","volume":"14","author":"Ninomiya N","year":"2003","journal-title":"J. Jpn Assoc. Acute Med"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.046391"},{"key":"e_1_2_6_19_2","first-page":"4941","article-title":"Phase I study of FUT\u2010175. Single and multiple dose study","volume":"12","author":"Abe H","year":"1984","journal-title":"Yakuri To Chiryou"},{"key":"e_1_2_6_20_2","first-page":"947","article-title":"Pharmacokinetic studies of regional anticoagulant\u2010FUT\u2010175 in hemodialysis","volume":"26","author":"Akizawa T.","year":"1989","journal-title":"Jin To Touseki"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1272\/jnms.72.43"},{"key":"e_1_2_6_22_2","first-page":"164","article-title":"Inhibitory effect of a new synthetic protease inhibitor (FUT\u2010175) on the coagulation system","volume":"15","author":"Hitomi Y","year":"1985","journal-title":"Homeostasis"},{"key":"e_1_2_6_23_2","first-page":"106","article-title":"A novel inhibitory mechanism for platelet aggregation by nafamostat mesilate","volume":"45","author":"Hodohara K.","year":"2005","journal-title":"Iyaku No Mon"},{"key":"e_1_2_6_24_2","first-page":"447","article-title":"Transition of the pharmacological action of Futhan centering on DIC","volume":"42","author":"Yoshikawa T","year":"2002","journal-title":"Iyaku No Mon"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.16.10689"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.284.5418.1313"},{"key":"e_1_2_6_27_2","first-page":"162","article-title":"NF\u2010\u03baB regulation","volume":"43","author":"Tuzuki H","year":"2003","journal-title":"Iyaku No Mon"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.285.5425.248"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200424916"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.shk.0000159930.87737.8a"}],"container-title":["Clinical and Experimental Pharmacology and Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1681.2007.04741.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1681.2007.04741.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T03:53:53Z","timestamp":1696910033000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1681.2007.04741.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,15]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["10.1111\/j.1440-1681.2007.04741.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1681.2007.04741.x","archive":["Portico"],"relation":{},"ISSN":["0305-1870","1440-1681"],"issn-type":[{"value":"0305-1870","type":"print"},{"value":"1440-1681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,15]]}}}